FTRE: Fortrea Corp Price-to-Sales Ratio

The price-to-sales ratio for Fortrea Holdings Inc. (FTRE) exhibits a downward trend as the consolidated CRO market faces pressure from AI technologies. The metric stands at 0.70, reflecting the global scale of early-phase research trials. However, a decline in biotech investment has weakened the pricing power of Fortrea Holdings Inc. (FTRE), forcing the company to offer discounts to ensure full capacity utilization of its laboratories.
Metric breakdowns and analytics for Fortrea Holdings Inc. (FTRE)

Fortrea Holdings Inc. generates revenue by providing specialized CRO drug testing services for the biopharmaceutical sector. The ratio of the business's market value to annual turnover, as reflected by the historical P/S, measures the model's ability to withstand industry shocks and technological pressure. It is critical for investors to benchmark this ratio against US market averages to identify overvaluation risks or signs of asset stagnation.